Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

STRO Sutro Biopharma Inc

1,9504

0,0204 (1,06%)

04 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Sutro Biopharma Charts.

News Sutro Biopharma Inc

Form 8-K - Current report
Dienstag 10 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Dienstag 10 Dezember 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 3 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 15 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Mittwoch 13 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Dienstag 12 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Montag 4 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Freitag 1 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Donnerstag 10 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 20 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Sutro Biopharma Inc News-Artikel

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen